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Abstract
Introduction: A well-functioning arteriovenous fistula (AVF) is the best modality for vascular access in patients with end-
stage renal disease (ESRD) requiring haemodialysis (HD). However, AVFs’ main disadvantage is the high rate of maturation
failure, with approximately one third (20%–50%) not maturing into useful access. This review examine the use of Far-Infra
Red therapy in an attempt to enhance both primary (unassisted) and secondary (assisted) patency rates for AVF in dialysis
and pre-dialysis patients.
Method: We performed an online search for observational studies and randomised controlled trials (RCTs) that evaluated
FIR in patients with AVF. Eligible studies compared FIR with control treatment and reported at least one outcome measure
relating to access survival. Primary patency and secondary patency rates were the main outcomes of interest.
Results: Four RCTs (666 patients) were included. Unassisted patency assessed in 610 patients, and was significantly better
among those who received FIR (228/311) compared to (185/299) controls (pooled risk ratio of 1.23 [1.12–1.35], p = 0.00001).
In addition, the two studies which reported secondary patency rates showed significant difference in favour of FIR therapy-
160/168 patients - compared to 140/163 controls (pooled risk ratio of 1.11 [1.04–1.19], p = 0.003).
Conclusion: FIR therapy may positively influence the complex process of AVF maturation improving both primary and
secondary patency rates. However blinded RCTs performed by investigators with no commercial ties to FIR therapy
technologies are needed.
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Introduction
The number of patients with end stage renal disease (ESRD)
requiring haemodialysis (HD) is steadily rising, a trend that is
expected to continue [1]. Vascular access is a critical component
in successful HD. A well-functioning arteriovenous fistula (AVF) is
the best modality for HD vascular access [2–6]. AVF maturation is
a complex process of remodelling. The newly formed fistula has to
form a low resistance circuit capable of dilation to accommodate
the increased blood flow required for HD. The AVF also has to be
cannulated repeatedly with ease. The need for re-intervention to
maintain patency should be minimal [2–4,6,7].
AVFs’ main disadvantage is the high rate of maturation failure,
with approximately one third (20%–50%) not maturing into useful
access [8–10]. AVFs have higher primary failure rates to mature
compared to grafts [8,11,12]. However they last longer, and with
exclusion of fistulas that fail to mature primarily, the cumulative
patency from formation to permanent failure is superior to grafts.
AVFs also require fewer secondary interventions in the form of
angioplasty, stenting or thrombectomy [8,13–16]. AVFs are
associated with fewer complications compared to AVG and
CVC in terms of infection, death, vascular access salvage
procedures and hospitalizations [15,16]. Also, a mature AVF has
a lower incidence of thrombosis and stenosis. This translates into
prolonged patency rates and lower risk for infection [1,17–20].
Maturation of AVF depends on variable biomechanical forces.
Remodelling of the arterial limb is characterised by vessel
dilatation and outward hypertrophic remodelling of the intimal
layer. Remodelling at the venous end can be accompanied by
aggressive intimal thickening resulting in inward hypertrophic
remodelling. Intimal hyperplasia (IH) is defined as the abnormal
migration and proliferation of vascular smooth muscle cells
provoked by injury, inflammation or stretch with associated
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Table 1. Results of the study quality assessment.
Included study Domain Support for judgement DH’s judgement
Lai 2013 ESVS [37] Random sequence
generation
The method of generating the random
sequence was not described.
Unclear
Allocation
concealment
No description of methods for
maintaining allocation concealment.
Unclear
Blinding of
participants and
personnel
Participants and personnel were not
blinded. Dysfunctional access signs and
other referral criteria could have a
subjective component.
High risk of bias
Blinding of outcome
assessment
Outcome assessors were not blinded.
Dysfunctional access signs and other
referral criteria could have a subjective
component.
High risk of bias
Incomplete outcome
data
Loss to follow up was minimal.
Analysis was not by intention to treat.
9/59 control group patients crossed over
to the intervention group potentially
leading to bias in favour of the
intervention
Unclear
Selective reporting No link to the protocol was given Unclear
Other sources of bias None Not available
Lin 2007
J Am Soc Neph [35]
Random sequence
generation
A computerised minimisation algorithm
was used
Low risk of bias
Allocation
concealment
Allocation sequence was kept by a study
nurse who would not disclose allocations
until time of intervention. Diagnosing
malfunction in a fistula could have had a
subjective element.
Unclear
Blinding of
participants and
personnel
Participants and personnel were not
blinded.
High risk of bias
Blinding of outcome
assessment
Outcome assessors were not blinded.
Diagnosing malfunction in a fistula could
have had a subjective element.
High risk of bias
Incomplete outcome
data
Loss to follow up was minimal and was
similar between groups and was unlikely
to influence results
Low risk of bias
Selective reporting Protocol was not available. Unclear
Other sources of bias None Not available
Lin 2013 AJKD [38] Random sequence
generation
A computer generated sequence was
used
Low risk of bias
Allocation
concealment
Sealed opaque envelope were used to
conceal allocation. There was no
information in the manuscript or protocol
on who had access to the envelopes and
whether they were opened sequentially
Unclear
Blinding of
participants and
personnel
No blinding. Diagnosing malfunction in a
fistula could have had a subjective element.
High risk of bias
Blinding of outcome
assessment
Ultrasonographers were blinded however
patients were not blinded. Diagnosing
malfunction in a fistula could have had a
subjective element.
High risk of bias
Incomplete outcome data Loss to follow up was similar between groups
and unlikely to influence results
Low risk of bias
Selective reporting Link to protocol was provided
(NCT01138254). Trial was not
prospectively registered and there were
several changes made including changes
to outcomes.
High risk of bias
Other sources of bias None Not available
Lin 2013 Neph Dial
Transplant [36]
Random sequence generation A computer generated sequence was used Low risk of bias
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deposition of extracellular matrix in the intimal layer of the vein
[21–23].
Far infra-red FIR therapy, which is a form of heat therapy, has
been implicated in improvement of endothelial function and
haemodynamics in coronary arteries, probably through up-
regulating endothelial nitric oxide synthase (eNOS) expression in
arterial endothelium leading to improved cardiac function in
patients with chronic heart diseases [24]. Repeated leg hyperther-
mia using FIR has been shown to reduce oxidative stress in bed
ridden type II diabetics [25].
FIR has also been reported to show encouraging results in
phantom limb pain control [26], stimulation of the secretion of
TGF-beta1 and activation of fibroblasts which may promote better
wound healing independent of skin blood flow and skin
temperature [27,28], reduction of both stress and fatigue levels
of patients with end stage renal disease (ESRD) and stimulates the
autonomic nervous system in those who are receiving regular
haemodialysis (HD) [29].
This review was designed to examine the effect of FIR on AVF
maturation using primary and secondary patency rates as the main
outcomes of interest.
Methods
This systematic review and meta-analysis were conducted
according to the Preferred Reporting Items for Systematic Review
and Meta-Analysis (PRISMA) guidelines [30].
Eligibility Criteria
We included observational studies or randomised controlled
trials (RCTs) that examined FIR therapy in patients with AVFs
and ESRD. Eligible studies reported on AVF patency rates in FIR
and non-FIR groups at one year or more following initiation of
FIR therapy. Cases series and case reports were excluded. There
was no restriction with regard to publication status or language.
Search strategy
A search of the literature for relevant studies was conducted in
March 2014. We searched Medline without date restriction using
the free text ‘‘far infra-red’’. Additionally we used the strategy
([‘‘far infra-red’’ OR ‘‘far infrared’’ OR ‘‘post conditioning’’]
AND [‘‘arteriovenous fistula’’ ‘‘dialysis’’ OR ‘‘end stage renal
disease’’ OR ‘‘dialysis access’’ OR ‘‘access survival’’ OR ‘‘primary
patency’’ OR ‘‘secondary patency’’ OR ‘‘fistula maturation]’’) to
search CINAHL, EMBASE, the Cochrane library and Google
Scholar. Bibliographies of included studies were searched for
additional studies.
Abstracts of the relevant titles were subsequently obtained and
evaluated for eligibility (KB, DH). Any remaining uncertainty was
resolved by examination of the full article (KB, DH). Discussion
with a third author (SRW) resolved discrepancies in cases of
disagreement regarding eligibility.
The relevant outcomes for this review were primary patency –
defined as unassisted AVF patency rates after at least 12 months of
follow up - and secondary patency – defined as assisted patency
rates after at least 12 months of follow up. The incidence of salvage
procedures (endoluminal procedures or surgical procedures) for
dysfunctional fistulas during follow up was a secondary outcome.
Data Collection
Data were extracted and checked for accuracy by two reviewers
(KB, DH) independently and recorded on a Microsoft Excel
spreadsheet. Any disagreements in extracting data were discussed
between two reviewers (KB, DH), and if not settled this was
resolved by consulting with a third reviewer (SRW). The following
information regarding participant characteristics were recorded:
age, sex, presence of co-morbidities, start of HD, primary and
secondary patency rates, AVF salvage procedures, underlying
cause of ESRD, definition of first AVF malfunction and overall
access survival. The trials’ inclusion and exclusion criteria were
also recorded.
Quality assessment for risk of bias
The risk of bias for each study was assessed according to the
criteria outlined in the in the Cochrane Handbook for Systematic
Reviews of Interventions [31]. For each included study; the
method used to perform random sequence generation, allocation
concealment and blinding was described. The study was then
Table 1. Cont.
Included study Domain Support for judgement DH’s judgement
Allocation
concealment
Sealed opaque envelope were used to
conceal allocation. Two study nurses
had access to the envelopes and there
was no information in the manuscript or
protocol on whether they were opened
sequentially
Unclear
Blinding of
participants and
personnel
No blinding. Diagnosing malfunction in a
fistula could have had a subjective element.
High risk of bias
Blinding of outcome
assessment
No blinding. Diagnosing malfunction in a
fistula could have had a subjective element.
High risk of bias
Incomplete outcome data Loss to follow up was similar between
groups and unlikely to influence results
Low risk of bias.
Selective reporting All outcomes that were mentioned in the
protocol were reported. The subgrouping
based on polymorphisms of heme
oxygenase-1 was not prespecified
Low risk of bias
Other sources of bias None Not available
doi:10.1371/journal.pone.0104931.t001
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scrutinised for incomplete data outcomes, selective reporting and
other potential sources of bias. Where possible, study protocols
were obtained from trial registries to ascertain whether there was
selective reporting within studies [Table 1].
Data analysis
Statistical analyses were performed using Review Manager
version 5.2.8 [32]. Pooled risk ratios were calculated using the
random effects model of DerSimonian and Laird [33]. For
Figure 1. PRISMA 2009 Flow Diagram.
doi:10.1371/journal.pone.0104931.g001
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continuous outcome variables the weighted mean difference
(WMD) was calculated. The presence of statistical heterogeneity
between studies was evaluated using the Cochran’s Q statistic. P-
values less than 5% were considered as statistically significant.
Publication bias was assessed visually using a funnel plot, and
additionally by comparing fixed and random effects modelling in a
sensitivity analysis – this is a recognised method that can detect the
influence of small-study effects [34].
Results
Study Selection
The results of the study selection process are summarized in the
PRISMA flow diagram (Figure 1). The initial search yielded a
total of 1669 citations, with 1244 citations remaining following
removal of duplicates. The titles of these citations were screened
with a total of 43 titles deemed potentially relevant. The abstracts
of those titles were examined and eight full text articles were
subsequently retrieved and examined. After assessing for eligibility
Table 2. Inclusion & exclusion criteria and definition of AVF malfunction for included studies.
Study Inclusion criteria Exclusion criteria Definition of AVF malfunction
Lin 2007 [35] (1) Receiving 4 h of maintenance
HD therapy three times weekly
for at least 6 months at Taipei
Veterans General Hospital,
(2) Using a native AVF as the
current vascular access for more
than 6 months, without
interventions within the last 3
months, and (3) Creation of
AVF by cardiovascular surgeons in
our hospital with the standardized
surgical procedures of venous
end-to-arterial side anastomosis
in the upper extremity.
During the 1-yr follow-up,
patients would be excluded
from the study because of the
following censoring criterion:
(1) Renal transplantation,
(2) Death with a functioning
access, (3) Shifting to peritoneal
dialysis, and (4) Loss of
follow-up.
The need for any interventional
procedure (surgery or angioplasty)
to correct an occlusive or
malfunctioning AVF that cannot
sustain an extracorporeal blood
flow .200 ml/min during HD after
exclusion of the following stenosis-unrelated
events: Infectious
complication, progressive
aneurysmal formation, or steal
syndrome.
Lin 2013_AJKD [38] (1) Aged 18–80 years, (2) Had
CKD with estimated glomerular
filtration rate (eGFR) of 5–
20 mL/min/1.73 m2, (3) Were
not anticipated to receive dialysis
or kidney transplantation within
the next 3 months, and (4) Were
undergoing AVF creation with
venous end-to-arterial side
anastomosis in the upper
extremity.
(1) Those receiving an
arteriovenous graft or cuffed
tunnelled double-lumen catheter
as the type of permanent vascular
access, (2) Heart failure of New
York Heart Association functional
class III or IV, and (3) Episode of
cardio- or cerebrovascular event or
receiving intervention therapy
within 3 months prior to screening.
The need for any interventional
procedure (surgery or angioplasty)
to correct an occlusive or
malfunctioning fistula which could
not sustain an extracorporeal blood
flow .200 mL/min during HD after
excluding the following stenosis-
unrelated events, such as infectious
complication, progressive
aneurysmal
formation or steal syndrome.
Lai_2013 [37] (1) Received two or more PTA on
the target lesions at upper
extremities, with the last PTA
successfully performed within the
week before patient enrolment, and
(2) After successful completion of
at least 1 week of HD treatment,
the patients with AVF or AVG
were consecutively enrolled and
randomly assigned to either a
post-PTA FIR radiation group
or a control group receiving the
usual form radiation therapy at a
1:1 ratio.
(1) Received HD treatments other
than three times a week, (2) Had
previously received FIR radiation
Therapy, (3) Received implantation
of an endovascular stent, (4) Had
multiple lesions that a single
radiation field did not cover or the
central lesion was considered too
deep to be irradiated, (5) Missed
FIR radiation treatments exceeding
10%, (6) Underwent renal
transplantation, (7) Switched to
peritoneal dialysis treatments, and
(8) Had any severe disease with an
estimated life expectancy of less
than 1 year.
A significant lesion was defined
as a lumen loss of 50% or more
compared with adjacent normal
vessel on angiography following
dysfunctional diagnosis based on
clinical signs suggestive of stenosis.
Lin_2013_NDT [36] (1) Receiving 4 h of maintenance
HD therapy three times weekly
for at least 6 months at Taipei
Veterans General Hospital,
(2) Using a native AVF as the
present vascular access for .6
months, without interventions
within the last 3 months,
and (3) Creation of AVF by
cardiovascular surgeons in our
hospital with the standardized
surgical procedures of venous
end-to-arterial side anastomosis
in the upper extremity.
Received an AV graft as the first
vascular access.
The need for any interventional
procedure (surgery or angioplasty)
to correct an occlusive or
malfunctioning fistula which could
not sustain an extracorporeal blood
flow .200 mL/min during HD after
excluding the following stenosis-
unrelated events, such as infectious
complication, progressive
aneurysmal formation or steal
syndrome.
doi:10.1371/journal.pone.0104931.t002
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criteria, four RCT’s were included in the review [35–38]. Three of
those studies reported on patients with history of previous AVF
who had been on HD prior to FIR therapy [35–37], while one
study reported on patients with newly formed AVF not on HD
[38]. We were not able to include another study by Lin et al [39]
with a follow up of 3 months for primary patency rates as it was a
conference abstract only, also we had concerns that the data in this
study was used in another study by the same author [36] that has
already been included in this review. Three studies were excluded
from the final analysis after going through the full articles. Shipley
et al followed their patients for six months in a case series of 20
patients – no control group - and reported maturation in 10 of
those patients [40]. Two studies did not report on the outcomes of
interest to the author of this systematic review [29,41].
Figure 2. Forest Plot showing Primary AVFs patency at 12 months.
doi:10.1371/journal.pone.0104931.g002
Figure 3. Funnel plot for Primary AVFs patency at 12 months.
doi:10.1371/journal.pone.0104931.g003
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Characteristics of included studies
Far Infrared (FIR) technique. All studies included used the
same technique for delivering of FIR therapy. WS TY101 FIR
emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei,
Taiwan) was used in all studies which generates electromagnetic
waves with wavelengths in the range between 5 and 25 (peak at 5–
8.2 mm). The top radiator was set at a height of 20–30 cm above
the surface of the AVF with the treatment time set at 40 min
during HD three times per week.
Participants
The four studies included 666 patients, with 340 patients
randomised to receive FIR therapy – median age 62.3614.5 SD,
while 326 were randomised to the control group – median age
62.0614.5 SD. 348 patients were males–180 in FIR group and
168 in the control group, while females were 318, of those 160
received FIR therapy and 158 were controls.
Inclusion and exclusion criteria of studies are outlined in
[Table 2], along with the definition of AVF malfunction for each
of the included studies.
Apart from Lin et al who evaluated the effects of FIR in pre-
dialysis patients with newly formed AVFs [38], the remaining
RCTs included patients who already started HD. Mean time on
HD in months for Lin et al [35] was 85.2641.1 for FIR group and
79.2642.2 for the control group, for Lai et al [37] FIR= 50.4642
and control = 58.8656.4 and for Lin et al in 2013 [36]
FIR= 66.0659.1 and control = 75.9658.0. All patients in includ-
ed trials received FIR therapy for 40 minutes per session three
times a week for the duration of the study.
Lai et al studied patients with history of dysfunctional AVFs and
repeated angioplasty. The mean life of the AVFs for their patients
was 21.8623.0 months for FIR group and 23.5622.6 months for
the controls [37]. 33 patients from 72 had history of AVF
malfunction and 14 patients required surgical intervention, while
20 patients had a total of 49 angioplasty procedures in the FIR
group compared to 34 patients from 73 with history of AVF
malfunction, 13 of those required surgical intervention and 20
patients with total of 46 angioplasty procedures in the control
group, in the RCT by Lin et al in 2007 [35]. Similarly, 47 patients
had history of AVF malfunction with 12 patients requiring surgery
from 139 and 35 patients underwent 79 angioplasty procedures in
the FIR group, compared to 45 patients with history of
malfunction, 13 patients of those required surgery and 32 patients
underwent angioplasty as a salvage procedure in the control group
in the study by Lin et al in 2013 [36]. All patients in both FIR and
control groups had angioplasty procedures prior to recruitment in
the study by Lai et al [37], while none of the patients included by
Lin et al had a history of either surgical or angioplasty salvage
procedures since they were all first time AVFs [38]. Lai et al had 9
of their patients who were initially randomised to the control
group crossing over to the FIR group based on their request [37].
Clinical maturation was reported in 49 (81.7%) patients of 60 who
received FIR therapy by Lin et all, compared to 37 (59.7%) from
the 62 control subjects [38]. Sub –group analysis by age, gender
and diagnosis of hypertension was not possible as this was not
included in studies, and we did not have access to the raw data
used by the authors. Other patients’ characteristics are detailed in
[Table 3].
Primary - unassisted - patency rates at 1 year
All of the 4 included studies (610 patients) reported on
unassisted – primary – patency rate after 12 months of follow-up
on the FIR therapy. 228/311 patients in FIR group had primarily
patent AVFs at 12 months compared to 185/299 patients in the
Figure 4. Forest Plot showing Primary AVFs patency at 12 months, Lin et al RCT on new AVFs excluded.
doi:10.1371/journal.pone.0104931.g004
Figure 5. Forest plot showing assisted patency rates at 12 months.
doi:10.1371/journal.pone.0104931.g005
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control group. Pooled results showed significant difference
between the two groups, with those who received FIR showing
better primary patency rates compared to control (Pooled risk
ratio = 1.23 [1.12, 1.35], 95% CI, p = 0.00001) [Figure 2]. There
was no evidence of statistical heterogeneity (Cochran’s Q=0.33;
degree of freedom (DF) = 3; p= 0.96; I2 = 0%). The funnel plot did
not suggest bias [Figure 3], and the result was unchanged when
fixed effects modelling was used (pooled risk ratio1.24 [1.13–1.37],
95% CI, p,0.0001).
Excluding the RCT by Lin et al on newly formed AVFs in pre-
dialysis patients [38] from the analysis for primary patency after 12
months, the remaining studies (490 patients) showed better results
in the FIR group with 176/252 AVFs being patent at 12 months
compared to 142/238 in the control group [35–37]. This was
statistically significant (Pooled risk ratio = 1.23 [1.10, 1.37], 95%
CI, p = 0.0001) [Figure 4]. There was no evidence of statistical
heterogeneity (Cochran’s Q=0.31; degree of freedom (DF) = 2;
p = 0.86; I2 = 0%).
Secondary - assisted - patency rates
Data could be retrieved from 2 studies (331 patients) for analysis
of assisted – secondary – patency rates at 12 months following
salvage procedures [36,38]. 160/168 patients in the FIR group
had patent AVFs following intervention for dysfunctional fistulas,
compared to 140/163 patients in the control arm. Pooled results
showed statistically significant difference favouring FIR therapy
(Pooled risk ratio = 1.11 [1.04–1.19]; 95% CI, p = 0.003) [Fig-
ure 5]. There was no evidence of statistical heterogeneity
(Cochran’s Q=0.71; degree of freedom (DF) = 1; p = 0.40;
I2 = 0%).
Intervention
Two studies [35,38] (249 patients) reported the need for
intervention to salvage a dysfunctional AVF. Patients who received
FIR therapy required less interventions, 11/123 patients com-
pared to 23/126 patients in the control group. The difference was
significant (Pooled risk ratio = 0.49 [0.25–0.985; 95% CI; p= 0.04)
[Figure 6]. There was no evidence of statistical heterogeneity
(Cochran’s Q=0.15; degree of freedom (DF) = 1; p = 0.70;
I2 = 0%).
Discussion
This review identified four studies (666 patients) which
evaluated the use of FIR therapy to improve primary and
secondary patency rates for AVFs in patients with ESRD. They all
reported significant improvement in the outcome measures
assessed in this review in favour of FIR therapy. Three of those
studies (490 patients) were carried out on patients already started
HD sessions, and one study (122 patients) focused on pre-dialysis
first time AVF maturation. All four trials following some form of
randomisation, and the demographics of patients in included
studies did not differ significantly. Pooled analysis showed that
primary - unassisted - patency was significantly better in the FIR
group (pooled risk ratio of 1.23 [1.12–1.35], p value of 0.0001).
Secondary – assisted – patency was reported in two studies (279
patients) and was found to be significantly better in those who
received FIR therapy (pooled risk ratio of 1.19 [1.07–1.31], p
value of 0.0008).
Post-conditioning using Far Infra-Red therapy has been shown
to increase the level of heme oxygenase-1 (HO-1) expression which
protects against Ischaemia/reperfusion injury in study by Tu et al
[42]. HO-1 is a known vasodilator and at the same time inhibits
proliferation of vascular smooth muscle cells, platelet aggregation,
and vasospasm leading to favourable conditions for maturation of
AVFs. Also, Ikeda et al repeated thermal therapy was shown to up-
regulate endothelial nitric oxide synthase expression in Syrian
hamsters [24], a finding that was validated by Akasaki et al, who
also reported increased angiogenesis via (eNOS) following
repeated thermal therapy in mice with hindlimb ischemia. [43].
Kipshidze et al irradiated cultures of rabbit endothelial cells and
smooth muscle cells with different doses of non-ablative infrared.
They found that non-ablative infrared laser inhibited neointimal
hyperplasia after coronary arteries angioplasty in cholesterol-fed
rabbits for up to 60 days [44]. FIR therapy is still considered a
novel treatment for AVF although the technique has been
described since 2007 by Lin et al [35]. This review demonstrated
a beneficial use of FIR therapy that improved both primary and
secondary patency rates across all studies included. This statisti-
cally significant difference was consistent even when one excluded
study for having only 3 months of follow-up was added to the
sensitivity analysis [39]. Also, excluding the only RCT found by
the authors on newly formed AVF did not alter the outcome of the
pooled analysis in terms of significance.
FIR therapy was also shown to improve access flow (Qa). The
study by Lin et al – which was one of the RCTs included in the
review - showed that 40 min of FIR therapy in a single HD session
could increase access flow of AVF by about 50 mL/min with a 1-
year effect of improving Qa by up to 150 mL/min and increasing
unassisted patency of AVF by about 18% in comparison with
controls [35].
A serious limiting factor of this systematic review is that the four
RCTs came from the same institution (Yang-Ming University in
Taiwan), and three of the four were authored by the same two
authors (Lin-cc and Yang-wc) [35,36,38]. Dr Lin-cc reported that
he was receiving lecture fees from WS Far Infrared Medical
Technology, the company that makes the infrared machines used
in the studies raising the potential of bias.
Figure 6. Forest plot showing surgical intervention for AVF malfunction.
doi:10.1371/journal.pone.0104931.g006
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Also, all the RCTs were performed in an unblinded fashion,
which can impact outcomes as demonstrated by the fact that in
one study nine patients opted to join the FIR group despite initially
being allocated as controls. Blinding in clinical trials involving FIR
therapy would involve additional costs in making machines that
resemble the ones used to deliver FIR therapy. Those machines
should be convincing to both staff and patients if effective double
blinding is to be considered. However, blinding can be attempted
by placing a screen between the FIR device and the patient. Also,
double-blinding can be achieved by placing a box over the device
and then creating simple mock devices that also appear as boxes.
This review provides a thorough examination of published
evidence supporting the use of FIR therapy to promote AVF
access maturation in patients with ESRD in HD, and also for
those who are likely to require dialysis in the near future. The
meta-analysis showed overwhelming support for regular use of
FIR therapy, however there were limitations that need to be
considered. Finally, this review may serve to guide future advances
in using repeated thermal therapy in postconditioning of AVFs.
Conclusion
Results from four RCTs suggest that regular use of FIR therapy
in haemodialysis and pre-haemodialysis patients, in particular
those with AVFs, can positively influence AVF function. However,
more blinded randomised controlled, multicentre and internation-
al clinical trials are required. We also hope to see sub-group
analysis in those studies, particularly by age (e.g. using 65 as cut-
off), gender and diagnosis of hypertension.
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